SK
TAK icon

Seth Klarman’s Takeda Pharmaceutical TAK Stock Holding History

Seth Klarman’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,434,803
Closed -$162M – 34
2019
Q3 		$162M Sell
9,434,803
-3,200
-0% -$55.3K 1.84% 20
2019
Q2 		$167M Sell
9,438,003
-1,231,018
-12% -$22.4M 1.51% 19
2019
Q1 		$217M Buy
+10,669,021
New +$215M 1.83% 18

Other funds holding TAK

GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Seth Klarman's TAK Position: Q4 2019 in Review

Seth Klarman sold out of Takeda Pharmaceutical (TAK) in Q4 2019, closing a stake of 9,434,803 shares — an estimated $162M sold.

Seth Klarman first reported a position in TAK in Q1 2019 and held it in 3 quarters. The position peaked at $217M in Q1 2019. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

  • Seth Klarman reported no remaining Takeda Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Seth Klarman sold 9,434,803 Takeda Pharmaceutical shares in Q4 2019, an estimated $162M.
  • Seth Klarman first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 3 quarters.
  • Seth Klarman's Takeda Pharmaceutical position peaked at $217M in Q1 2019.
  • 339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on Baupost Group's 13F filing for Q4 2019, filed 13 Feb 2020.